#Australia #Colossal Foundation #Hobart #Tasmanian Devil #DFTD

New Strategies to Combat Devil Facial Tumour Disease

The Colossal Foundation has forged a groundbreaking alliance with the University of Tasmania to tackle the pressing issues posed by Devil Facial Tumour Disease (DFTD). This fatal cancer, transmitted among Tasmanian devils, has wreaked havoc on their populations, resulting in a staggering 80% decline in the species across Tasmania. The initiative aims to leverage advanced vaccine development alongside innovative gene-editing technology to provide these iconic marsupials a fighting chance against extinction.

The Urgency of Conservation

Founded by Colossal Biosciences, the Colossal Foundation is dedicated to conservation efforts utilizing cutting-edge technology to prevent the extinction of keystone species. The Tasmanian devil, renowned as the world's largest carnivorous marsupial, is in dire straits due to DFT1 and DFT2, two transmissible cancers that severely compromise their health and survival.

Wild populations of Tasmanian devils have plummeted since the disease's emergence in the mid-90s, impacting not only the devils themselves but also the broader ecological landscape. As apex predators, these creatures play a pivotal role in maintaining the balance of their ecosystems, controlling feral species and safeguarding native fauna. Their diminishing numbers pose a significant risk not only to their species but to the entire Tasmanian environment.

Two-Pronged Combat Strategy

To counteract these challenges, the collaborative effort focuses on two primary strategies: vaccines and gene editing. Associate Professor Andrew Flies of the University of Tasmania leads the Wild Immunology Group, which has been developing an advanced oral vaccine designed to bolster the immune response of Tasmanian devils against DFTD. This vaccine could be administered through bait, allowing for a more accessible method to safeguard free-ranging devils in their natural habitat.

Simultaneously, the partnership looks to use gene editing to address the biological vulnerabilities contributing to DFTD susceptibility. Specifically, researchers will focus on the LZTR1 gene, which has been identified as relevant to the tumor’s development in Tasmanian devils. By aiming to modify mutations found in this gene, scientists hope to enhance the devils' resistance to transmissible cancers, providing them with a long-term solution to combat these diseases.

Menzies Institute for Medical Research: A New Hub for Innovation

As part of this initiative, a research colony of fat-tailed dunnarts will be established at the Menzies Institute for Medical Research in Hobart. This proximity to Tasmanian devils provides a unique opportunity to test vaccine efficacy and safety, as the dunnart is closely related and serves as a suitable model for research. Engaging veterinary professionals and animal care teams will ensure the successful transfer of critical veterinary and care protocols necessary for dunnart husbandry and breeding.

The fat-tailed dunnart has re-emerged as an instrumental model in marsupial research due to the advancements made through Colossal's de-extinction efforts, which previously focused on the thylacine. This research has opened up new avenues for managing living species, promoting both plant and animal conservation efforts in Australia.

Community Collaboration and Support

This partnership is bolstered by the backing of wildlife rescue organizations, including Bonorong Wildlife Sanctuary, which has been at the forefront of efforts to rehabilitate Tasmanian devils. Greg Irons, Director of Bonorong, emphasizes the pressing need for innovative solutions amid the ongoing crisis.

Community and organizational support extends further through the Tasmania Thylacine Advisory Committee, which seeks to fortify the collaboration for the benefit of local wildlife conservation, enhancing the community's stake in preserving this emblematic species.

The Future of Conservation and De-Extinction

Colossal Foundation's work epitomizes the potential of de-extinction science to bring immediate benefits to pressing conservation issues. By fusing innovative technology with traditional conservation methods, they are spearheading new approaches to combat wildlife diseases, aiming not just for recovery but to restore balance in Tasmania's ecosystems.

In conclusion, the collaboration between the Colossal Foundation and the University of Tasmania signifies a hopeful leap forward in combating DFTD and safeguarding the future of the Tasmanian devil. As these innovative strategies take shape, they offer a model for other conservationists facing similar challenges worldwide, demonstrating the power of scientific collaboration in preserving our natural heritage.